Investing in Tarsus Pharmaceuticals involves evaluating a commercial-stage biopharmaceutical company focused on novel treatments for ophthalmic and dermatologic conditions, anchored by its flagship FDA-approved product for Demodex blepharitis. The company has shown promising commercial adoption rates and revenue expansion trajectories since launching its lead therapeutic. Nevertheless, potential investors must weigh these commercial milestones against high operational expenses, ongoing sales and marketing investments, and general market risks common among emerging specialty pharmaceutical growth equities.